Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. AbuRuz SM, Bulatova NR, Yousef AM. Validation of a comprehensive classification tool for treatment-related problems. Pharm World Sci. 2006;28:222–32.
2. CDC. COVID-19 and People at Increased Risk [Internet]. 2021. https://www.cdc.gov/drugoverdose/resources/covid-drugs-QA.html. Accessed 13 Jul 2022.
3. NIH. COVID-19 & Substance Use [Internet]. 2020. https://nida.nih.gov/research-topics/comorbidity/covid-19-substance-use. Accessed 13 Jul 2021.
4. Skalafouris C, Samer C, Stirnemann J, Grosgurin O, Eggimann F, Grauser D, et al. Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19. Eur J Hosp Pharm Sci Pract [Internet]. 2021. https://ejhp.bmj.com/content/early/2021/04/07/ejhpharm-2020-002667.
5. Iloanusi S, Mgbere O, Essien EJ. Polypharmacy among COVID-19 patients: a systematic review. J Am Pharm Assoc. 2021;61(5):e14-25.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献